Daniel Zingg - Principal Scientist, Discovery Oncology

Daniel Zingg

Principal Scientist, Discovery Oncology

Awards & Honors

 I completed my PhD at the University of Zurich, Switzerland, in 2015 training as a cancer biologist focusing on the various roles of epigenetic modifiers in cutaneous melanoma development. Until 2018, I continued working on the epigenetic regulation in melanoma as a postdoctoral fellow. In 2018, I joined the Netherlands Cancer Institute, The Netherlands,  as a senior postdoctoral fellow focusing on oncogenic variant classification, tumor initiation mechanisms, and targeted therapy resistance centered around the RTK FGFR2.

I joined Genentech in 2023 for several reasons, namely, the outstanding scientists, the collaborative culture that encourages team science, and real patient impact. Here, I collaborate across departments to understand the mechanisms of cell cycle control in cancer, ultimately identifying tumor-specific vulnerabilities that can be therapeutically exploited. 

Featured Publication

MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

J Exp Med (2023) 220 (11): e20211743.

Bhin et al.,

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

Nature 608, 609–617 (2022).

Zingg et al.,

EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.

Cancer Cell (2018) Jul 9;34(1):69-84.e14.

Zingg et al.,